L-arginine supplementation reduces mortality and improves disease outcome in mice infected with <i>Trypanosoma cruzi</i>
Sofía Carbajosa
Héctor O. Rodríguez-Angulo
Susana Gea
Carlos Chillón-Marinas
Cristina Poveda
María C. Maza
Diana Colombet
Manuel Fresno
Núria Gironès
10.1371/journal.pntd.0006179
https://plos.figshare.com/articles/dataset/L-arginine_supplementation_reduces_mortality_and_improves_disease_outcome_in_mice_infected_with_i_Trypanosoma_cruzi_i_/5790072
<div><p>Chagas disease caused by <i>Trypanosoma cruzi</i> is a neglected disease that affects about 7 million people in Latin America, recently emerging on other continents due to migration. As infection in mice is characterized by depletion of plasma L-arginine, the effect on infection outcome was tested in mice with or without L-arginine supplementation and treatment with 1400W, a specific inhibitor of inducible nitric oxide synthase (iNOS). We found that levels of L-arginine and citrulline were reduced in the heart and plasma of infected mice, whereas levels of asymmetric dimethylarginine, an endogenous iNOS inhibitor, were higher. Moreover, L-arginine supplementation decreased parasitemia and heart parasite burden, improving clinical score and survival. Nitric oxide production in heart tissue and plasma was increased by L-arginine supplementation, while pharmacological inhibition of iNOS yielded an increase in parasitemia and worse clinical score. Interestingly, electrocardiograms improved in mice supplemented with L-arginine, suggesting that it modulates infection and heart function and is thus a potential biomarker of pathology. More importantly, L-arginine may be useful for treating <i>T</i>. <i>cruzi</i> infection, either alone or in combination with other antiparasitic drugs.</p></div>
2018-01-16 18:33:18
Nitric oxide production
Trypanosoma cruzi Chagas disease
plasma
infection
iNOS
inducible nitric oxide synthase
heart parasite burden
L-arginine supplementation